Evidence map›Paper›PMID 41079886›Full record

ArticleEndocrine oncology (Bristol, England)2025

Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes.

Alexander R Goldberg, Cheng Liu, Gary D Rothberger, Kepal N Patel, Rong Xia, Steven Hodak, Sumedha Chablani

Abstract read
In one paragraph

Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander R GoldbergHolman Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0009-0005-7343-8729
Cheng LiuDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Gary D RothbergerHolman Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Kepal N PatelDivision of Endocrine Surgery, Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
Rong XiaDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Steven HodakHolman Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Sumedha ChablaniHolman Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While traditional risk stratification for thyroid cancer primarily focused on tumor pathology, molecular profiling is increasingly recognized for its clinical relevance. There are limited data on tumors with three or more mutations, especially when presenting with non-malignant cytology. This study aims to evaluate the clinical behavior of cytologically non-malignant thyroid nodules with three or more potent oncogenic mutations. Methods: Electronic medical records of patients at our institution with thyroid nodules who underwent molecular testing were reviewed to identify cases with cytologically benign or indeterminate thyroid nodules that harbored three or more oncogenic mutations. Clinical, cytological, and molecular data were analyzed to assess tumor behavior. Results: Four of six cases were histologically malignant at index surgery. One histologically benign case developed distant metastases 7 years later. Retrospective analysis of the two histologically benign cases and the one case with low-risk histology demonstrated significant intratumoral heterogeneity. The benign case that developed distant metastases was found to have an area of intratumoral heterogeneity whose genetic profile matched the metastases. Conclusions: Despite bland cytological and ultrasonographic features, these tumors exhibited aggressive behavior. The molecular profile of thyroid cancers should be considered when determining treatment, especially in cases with multiple high-risk mutations, as they may behave more aggressively than predicted by cytology or imaging alone.

Indexed as

cytologyEIF1AX mutationRAS mutationTERT mutationthyroid cancerthyroid genetics

Identifiers

PMID41079886
PMCPMC12508729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.